Amylyx Pharmaceuticals (AMLX) investor relations material

Executive summary

• Completed enrollment for pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH); topline data expected Q3 2026, with commercial launch preparations underway and potential launch in 2027 if approved.

• Initiated U.S. Expanded Access Program for avexitide, addressing urgent patient need and ensuring continuity for trial participants.

• Progressed pipeline: IND-enabling studies for AMX0318, positive Phase II data for AMX0035 in Wolfram syndrome, and Phase I LUMINA trial for AMX0114 in ALS.

• Cash runway projected to fund operations through potential avexitide commercialization and into 2028.

Financial highlights

• Ended Q1 2026 with $279.8 million in cash, cash equivalents, and marketable securities, down from $317 million at end of Q4 2025.

• Net loss for Q1 2026 was $41.3 million ($0.37/share), a 15% increase from $35.9 million ($0.42/share) in Q1 2025.

• Total operating expenses were $43.8 million, up from $37.8 million in Q1 2025.

• R&D expenses rose to $27.6 million from $22.1 million in Q1 2025, mainly due to avexitide clinical development and $4 million milestone payment to Gubra for AMX0318.

• Selling, general, and administrative expenses increased to $16.2 million, reflecting commercial launch preparations and higher consulting costs.

Outlook and guidance

• Cash runway expected into 2028, supporting key milestones including LUCIDITY readout, potential FDA approval, and commercial launch of avexitide in 2027.

• IND filing for AMX0318 targeted for 2027.

• Longer-term data for AMX0035 in Wolfram syndrome and early biomarker data for AMX0114 in ALS expected at upcoming scientific meetings.